Fuding Guo

Dr. Fuding Guo


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2023 in Journal of Medical Internet Research
Verified
Journal Article
Open access
YWYijun Wang
Yijun Wang
FGFuding Guo
Fuding Guo
JWJun Wang
Jun Wang
ZLZeyan Li
Zeyan Li
WTWuping Tan
Wuping Tan
LYLilei Yu
Lilei Yu
Background: The advantages of multimodal digitally transformed mobile health management for patients diagnosed with mild to moderate hypertension are not yet established. Objective: We aim to evaluate the therapeutic benefits of a novel WeChat-based multimodal digital transforming management model in mobile health blood pressure (BP) management. Methods: This randomized controlled clinical trial included 175 individuals with new-onset mild to moderate hypertension who were admitted to our center between September and October 2022. The patients were randomly assigned to either the multimodal intervention group (n=88) or the usual care group (n=87). The primary composite outcome was home and office BP differences after 6 months. The major secondary outcomes were 6-month quality-of-life scores, including the self-rating anxiety scale, self-rating depression scale, and Pittsburgh Sleep Quality Index. Results: The mean home BP decreased from 151.74 (SD 8.02)/94.22 (SD 9.32) to 126.19 (SD 8.45)/82.28 (SD 9.26) mm Hg in the multimodal intervention group and from 150.78 (SD 7.87)/91.53 (SD 9.78) to 133.48 (SD 10.86)/84.45 (SD 9.19) mm Hg in the usual care group, with a mean difference in systolic blood pressure and diastolic blood pressure of –8.25 mm Hg (95% CI –11.71 to –4.78 mm Hg; P<.001) and –4.85 mm Hg (95% CI –8.41 to –1.30 mm Hg; P=.008), respectively. The mean office BP decreased from 153.64 (SD 8.39)/93.56 (SD 8.45) to 127.81 (SD 8.04)/ 82.16 (SD 8.06) mm Hg in the multimodal intervention group and from 151.48 (SD 7.14)/(91.31 (SD 9.61) to 134.92 (SD 10.11)/85.09 (SD 8.26) mm Hg in the usual care group, with a mean difference in systolic blood pressure and diastolic blood pressure of –9.27 mm Hg (95% CI –12.62 to –5.91 mm Hg; P<.001) and –5.18 mm Hg (95% CI –8.47 to –1.89 mm Hg; P=.002), respectively. From baseline to 6 months, home BP control <140/90 mm Hg was achieved in 64 (72.7%) patients in the multimodal intervention group and 46 (52.9%) patients in the usual care group (P=.007). Meanwhile, home BP control <130/80 mm Hg was achieved in 32 (36.4%) patients in the multimodal intervention group and 16 (18.4%) patients in the usual care group (P=.008). After 6 months, there were significant differences in the quality-of-life total and graded scores, including self-rating anxiety scale scores (P=.04), self-rating depression scale scores (P=.03), and Pittsburgh Sleep Quality Index scores (P<.001), in the multimodal intervention group compared with the usual care group. Conclusions: The WeChat-based multimodal intervention model improved the BP control rates and lowered the BP levels more than the usual care approach. The multimodal digital transforming management model for hypertension represents an emerging medical practice that utilizes the individual’s various risk factor profiles for primary care and personalized therapy decision-making in patients with hypertension. Trial Registration: Chinese Clinical Trial Registry ChiCTR2200063550; https://www.chictr.org.cn/showproj.html?proj=175816

17 April 2025 in Medical Gas Research
Verified
Journal Article
Open access
MTMenglin Tian
Menglin Tian
WDWenyin Du
Wenyin Du
SYSen Yang
Sen Yang
QLQiwei Liao
Qiwei Liao
FGFuding Guo
Fuding Guo
SLShaolong Li
Shaolong Li
Cardiovascular diseases remain the leading cause of death worldwide, underscoring the urgent need for additional therapeutic strategies to reduce their mortality rates. This review systematically outlines the historical development and recent advances of hyperbaric oxygen therapy in cardiovascular diseases, with a focus on its therapeutic mechanisms and clinical outcomes. Hyperbaric oxygen therapy enhances oxygen delivery to ischemic and reperfused tissues, promotes angiogenesis, and significantly suppresses oxidative stress, inflammatory cascades, and cardiomyocyte apoptosis, demonstrating multifaceted therapeutic potential in cardiovascular conditions. Specifically, hyperbaric oxygen therapy combined with reperfusion strategies has been shown to markedly improve left ventricular ejection fraction in acute myocardial infarction. In heart failure, it facilitates myocardial repair and enhances cardiac function. For arrhythmias, hyperbaric oxygen therapy effectively reduces the frequency and duration of premature ventricular contractions and paroxysmal tachycardia, while mitigating the risk of neurological complications following atrial fibrillation ablation. Furthermore, hyperbaric oxygen therapy preconditioning in cardiac surgery has demonstrated improvements in left ventricular stroke work, reductions in postoperative myocardial injury, and a decrease in related complications. Despite its promising applications, the widespread adoption of hyperbaric oxygen therapy remains hindered by the lack of standardized treatment protocols and high-quality evidence from rigorous clinical trials. In conclusion, this review underscores the potential value of hyperbaric oxygen therapy in the cardiovascular domain while highlighting the need for further optimization of therapeutic parameters and exploration of its synergistic effects with conventional therapies to provide clearer guidance for clinical implementation.

11 March 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
XSXiaoyu Shi
Xiaoyu Shi
YWYijun Wang
Yijun Wang
YWYuhong Wang
Yuhong Wang
JWJun Wang
Jun Wang
CPChen Peng
Chen Peng
LYLilei Yu
Lilei Yu
Background: Digital education for outpatient patients with atrial fibrillation (AF) has gradually increased. However, research on digital education for patients undergoing atrial fibrillation catheter ablation (AFCA) is limited. Objective: This study aimed to develop a novel digital animation-based multistage education system and evaluate its quality-of-life benefits for patients with AFCA. Methods: This randomized controlled clinical trial included 208 patients with AF who underwent catheter ablation in the Department of Cardiology at Renmin Hospital of Wuhan University between January 2022 and August 2023. The patients were randomly assigned to the digital animation intervention (n=104) and standard treatment (n=104) groups. The primary outcome was the difference in the quality of life of patients with atrial fibrillation (AF-QoL-18) scores at 3 months. Secondary outcomes included differences in scores on the 5-item Medication Adherence Report Scale (MARS-5), Self-rating Anxiety Scale (SAS), and Self-Rating Depression Scale (SDS) at 3 months. Results: In the digital animation intervention group, the AF-QoL-18 score increased from 38.02 (SD 6.52) to 47.77 (SD 5.74), the MARS-5 score increased from 17.04 (SD 3.03) to 20.13 (SD 2.12), the SAS score decreased from 52.82 (SD 8.08) to 45.39 (SD 6.13), and the SDS score decreased from 54.12 (SD 6.13) to 45.47 (SD 5.94), 3 months post discharge from the hospital. In the conventional treatment group, the AF-QoL-18 score increased from 36.97 (SD 7.00) to 45.31 (SD 5.71), the MARS-5 score increased from 17.14 (SD 3.01) to 18.47 (SD 2.79), the SAS score decreased from 51.83 (SD 7.74) to 47.31 (SD 5.87), and the SDS score decreased from 52.78 (SD 5.21) to 45.37 (SD 6.18). The mean difference in AF-QoL-18 score change between the 2 groups was 1.41 (95% CI 2.42-0.40, P=.006) at 3 months. The mean difference in MARS-5 score change was 1.76 (95% CI 2.42-1.10, P<.001). The mean difference in SAS score was –2.91 (95% CI –3.88 to –1.95, P<.001). Additionally, the mean difference in SDS score was –1.23 (95% CI –0.02 to –2.44, P=.047). Conclusions: Our study introduces a novel digital animation educational approach that provides multidimensional, easily understandable, and multistage education for patients with AF undergoing catheter ablation. This educational model effectively improves postoperative anxiety, depression, medication adherence, and quality of life in patients at 3 months post discharge. Trial Registration: Chinese Clinical Trial Registry ChiCTR2400081673; https://www.chictr.org.cn/showproj.html?proj=201059

13 April 2020 in Cardiology Research and Practice
Verified
Journal Article
Open access
PDF file
WHWei Hu
Wei Hu
JXJing Xie
Jing Xie
TZTongjian Zhu
Tongjian Zhu
GMGuannan Meng
Guannan Meng
MWMeng Wang
Meng Wang
HJHong Jiang
Hong Jiang
Purpose. Recent studies have indicated that N-acetylneuraminic acid (Neu5Ac) plays a key role in severe coronary artery diseases, involving RhoA signaling pathway activation, which is critically involved in cardiac fibrosis. There is convincing evidence from many studies that left atrium fibrosis is involved in the pathophysiology of AF. Therefore, we speculated that Neu5Ac may be associated with atrial fibrillation (AF) and involved in the development of AF. This study aims to investigate the clinical relationship between Neu5Ac and AF and left atrial enlargement. Methods. Forty-five patients with AF (AF group) and forty-five patients with non-AF (control group) matched for age, sex, and hospitalization date were recruited for our study. Plasma concentrations of Neu5Ac from peripheral venous blood were analyzed using enzyme-linked immunosorbent assay (ELISA). The baseline characteristics, plasma level of Neu5Ac, and echocardiographic characteristics were evaluated. Results. The plasma level of Neu5Ac was significantly higher in the AF group than in the control group (107.66 ± 47.50 vs 77.87 ± 39.09 ng/ml; P<0.05); the left atrial diameters were positively correlated with the plasma Neu5Ac level (R = 0.255; P<0.05). The plasma Neu5Ac level (R = 0.368; P<0.05) and the left atrial diameters (R = 0.402; P<0.05) were positively correlated with AF history times. Neu5Ac (odds ratio 1.018, 95% CI 1.003–1.032; P<0.05) and the left atrial diameter (odds ratio 1.142, 95% CI 1.020–1.280; P<0.05) were independent risk factors for AF in multivariate regression analysis. Conclusions. Serum Neu5Ac is associated with atrial fibrillation, and the mechanism may involve left atrial enlargement.

22 August 2025 in Heart Rhythm O2
Verified
Journal Article
Open access
HLHongxi Li
Hongxi Li
HZHan Zhang
Han Zhang
MTMenglin Tian
Menglin Tian
SYSen Yang
Sen Yang
XZXiaohua Zhao
Xiaohua Zhao
FGFuding Guo
Fuding Guo
Ventricular arrhythmias (VAs), particularly scar-related ventricular tachycardia, remain a leading cause of sudden cardiac death in patients with structural heart disease. Although radiofrequency ablation is the current standard of care, its efficacy is limited in complex myocardial substrates. Pulsed field ablation (PFA), a non-thermal and cell-selective technique based on irreversible electroporation, has emerged as a promising alternative. This review provides a comprehensive overview of the mechanistic rationale, preclinical validation, and early clinical experiences of PFA in VAs. It primarily discusses potential challenges in the clinical treatment of ventricular tachycardia. Furthermore, we highlight emerging catheter systems and the possible synergistic value of functional substrate mapping, preprocedural imaging, and parameter optimization in improving the precision and safety of PFA. As a promising ablation technology, PFA holds strong potential for treating VAs.

10 October 2025 in Journal of Medical Systems
Verified
Journal Article
Closed access
PDF file
MTMenglin Tian
Menglin Tian
SLShaolong Li
Shaolong Li
WDWenyin Du
Wenyin Du
SYSen Yang
Sen Yang
XZXiaohua Zhao
Xiaohua Zhao
FGFuding Guo
Fuding Guo